Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 8/20 | 0.53 |
| ▸ | CCND1 | P24385 | 8/20 | 0.53 |
| ▸ | CCND2 | P30279 | 8/20 | 0.53 |
| ▸ | CCND3 | P30281 | 8/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135183 | 0.89 | MERTK (0.42) | MERTKCDK4CCND1CCND2CCND3 | |
| SCHEMBL6133749 | 0.85 | TP53 (0.44) | MERTKCDK4CCND1CCND2CCND3 | |
| SCHEMBL6134592 | 0.84 | ADORA1 (0.47) | MERTKMEN1KMT2ACCNA2CDK2 | |
| SCHEMBL6134405 | 0.83 | KDM4E (0.40) | MERTKCDK4CCND1CCND2CCND3 | |
| SCHEMBL6134310 | 0.83 | GAA (0.45) | MERTKCYP1A2CYP2C19CCNA2CDK2 | |
| SCHEMBL6135441 | 0.83 | POLB (0.47) | MERTKMEN1KMT2ACCNA2CDK2 | |
| SCHEMBL6134324 | 0.82 | ADORA1 (0.47) | KMT2A | |
| SCHEMBL6134588 | 0.82 | ADORA1 (0.48) | MERTKMEN1KMT2A | |
| SCHEMBL6135245 | 0.82 | CCNA2 (0.40) | MERTKMEN1USP2KMT2AHIF1A | |
| SCHEMBL6133427 | 0.81 | LMNA (0.46) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | MERTK 2751/4885CDK4 1261/4885CCND1 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.